Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kalenika Group appears to be a Russia-based private manufacturing and export company rather than a biotechnology or pharmaceutical developer. Publicly available trade-directory and company-profile sources describe it as established in 2004, headquartered in Moscow, and active in products including humic acid fertilizers, organo-mineral fertilizers, turboexpander equipment, and taxifolin (dihydroquercetin). The presence of taxifolin, a bioactive flavonoid ingredient sometimes sold into healthcare, food, beverage, or cosmetics markets, gives the company a limited health-adjacent angle, but the overall business does not appear to be a life sciences R&D company with a therapeutic pipeline. No evidence was found of clinical-stage drug development, regulated therapeutics, or a biotech platform. Based on the available evidence, Kalenika Group is best characterized as a commercial supplier of industrial/agricultural and specialty ingredient products.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Kalenika Group.